LZLi-Juan Zhou

Li-Juan Zhou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Li-Juan Zhou has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Chun-Lei Shan

    Department of Pharmacy, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China

    1 shared publication
  • Dan Zhao

    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX 77030

    1 shared publication
  • Honggang Liu

    Department of Pathology, Beijing Tongren Hospital, Capital Medical University, Beijing Key Laboratory of Head and Neck Molecular Diagnostic Pathology, Beijing, China

    1 shared publication
  • Kun Li

    Department of Otolaryngology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China

    1 shared publication
  • Lei Liu

    Department of Orthopaedics Shaoxing Hospital of Traditional Chinese Medicine Shaoxing China

    1 shared publication
  • Li-Hua Sun

    Department of Diagnostic Ultrasound & Echocardiography, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China

    1 shared publication

Latest Publications

  • Open Access

    Chinese herbal injections for coronavirus disease 2019 (COVID-19): A narrative review

    by Xiao-Bin Zhu, Meng Guo, Zhi-Hui Zhang, Li-Hua Sun, Lei Liu, Li-Juan Zhou, Chun-Lei Shan, Yi Yang, Lian-Di Kan, Liu-Cheng Li


  • Open Access

    MUC5AC enhances tumor heterogeneity in lung adenocarcinoma with mucin production and is associated with poor prognosis

    by Yujie Dong, Lijuan Zhou, Dan Zhao, Kun Li, Zichen Liu, Nanying Che, Honggang Liu

    Objective: The clinicopathological significance of Mucin5AC (MUC5AC) in lung adenocarcinoma with mucin production is still unclear. This study aimed to explore MUC5AC expression in lung adenocarcinoma with mucin production and its correlation with histological subtypes, common driver mutations and its impact on prognosis. Methods: MUC5AC and thyroid transcription factor 1 immunohistochemistry was performed on surgical samples from 90 patients with lung adenocarcinoma with mucin production. Common driver mutations including EGFR and KRAS mutations and ALK rearrangement were detected by established methods. Results: MUC5AC was significantly associated with lymphovascular invasion (P = 0.023) and tumors with intra-cytoplasmic mucin (P < 0.001). Moreover, MUC5AC was more significant in invasive mucinous adenocarcinoma (P < 0.001), as well as in tumors with KRAS mutations (P = 0.005) and a lack of thyroid transcription factor 1 expression (P < 0.001). Conversely, MUC5AC was less significantly detected in acinar predominant adenocarcinoma (P = 0.036) and tumors with EGFR mutations (P = 0.001). Notably, MUC5AC in non-pure mucinous subtype of lung adenocarcinoma with mucin production showed more aggressive behavior, distinct expression pattern and a lack of significant correlation with thyroid transcription factor 1 (P = 0.113) when compared with pure mucinous subtype. MUC5AC-positive tumors were significantly associated with a worse prognosis compared to MUC5AC-negative tumors (P < 0.001). A multivariate survival analysis showed that MUC5AC was an independent prognosis factor for poor prognosis (P = 0.006). Conclusions: The clinicopathological features of non-pure mucinous subtype of lung adenocarcinoma with mucin production were distinct and should be distinguished from pure mucinous subtype. MUC5AC was associated with poor prognosis and could be a potential therapeutic target for this distinct type of lung adenocarcinoma that has few effective treatments.